Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma

Previous studies demonstrated the relevance of focal lesions (FL) in whole-body magnetic resonance imaging (wb-MRI) at the initial workup of patients with smoldering multiple myeloma (SMM). The aim of this study was to assess the effects of longitudinal wb-MRIs on progression into multiple myeloma (MM). Sixty-three patients with SMM were analyzed who received at least two wb-MRIs for follow-up before progression into MM. Radiological progressive disease (MRI-PD) was defined as detection of new FL or increase in diameter of existing FL and a novel or progressive diffuse infiltration. Radiological stable disease (MRI-SD) was defined by no change compared with the prior MRI. Patients were followed-up every 3–6 months, including a serological and clinical evaluation. One Hundred and eighty-two wb-MRIs were analyzed. MRI-PD occurred in 31 patients (49%), and 25 (40%) patients developed MM. MRI-PD was highly significantly associated with progression into MM, regardless of findings at the initial MRI. In multivariate analysis, MRI-PD remained a risk factor, independent of relevant baseline parameters like serum monoclonal protein or ⩾95% aberrant plasma cells in the bone marrow. Patients with MRI-SD had no higher risk of progression, even when FL were present at the initial MRI. Therefore, MRI is suitable for the follow-up of patients with SMM.

[1]  H. Kauczor,et al.  Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. , 2009, Radiology.

[2]  M. Dimopoulos,et al.  Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients , 2012, American journal of hematology.

[3]  Tobias Bäuerle,et al.  Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Therneau,et al.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. , 2007, The New England journal of medicine.

[5]  E. Giné,et al.  Smoldering multiple myeloma: natural history and recognition of an evolving type , 2003, British journal of haematology.

[6]  T. Therneau,et al.  Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. , 2008, Blood.

[7]  R. Fonseca,et al.  Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma , 2013, Leukemia.

[8]  E Terpos,et al.  International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma , 2009, Leukemia.

[9]  A. Órfão,et al.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. , 2007, Blood.

[10]  S. Kristinsson,et al.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. , 2011, Blood.

[11]  B. Barlogie,et al.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.

[12]  F. Prósper,et al.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. , 2013, The New England journal of medicine.

[13]  D. Hose,et al.  Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma , 2012, Haematologica.

[14]  R Simon,et al.  A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.

[15]  E. Zamagni,et al.  The role of imaging techniques in the management of multiple myeloma , 2012, British journal of haematology.

[16]  M. Dimopoulos,et al.  Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease , 2013, Leukemia.

[17]  M. Dimopoulos,et al.  Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  O. Landgren,et al.  Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma” , 2013, Leukemia & lymphoma.

[19]  M. Dimopoulos,et al.  Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Hose,et al.  Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Guermazi,et al.  Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma , 1999, British journal of haematology.

[22]  B. Barlogie,et al.  Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Reiser,et al.  Role of MRI for the diagnosis and prognosis of multiple myeloma. , 2005, European journal of radiology.

[24]  M. Dimopoulos,et al.  Advances in imaging and the management of myeloma bone disease. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Choyke,et al.  Current and future imaging modalities for multiple myeloma and its precursor states , 2011, Leukemia & lymphoma.